Phase 2 data presentation expands on top-line findings, reinforcing efimosfermin as a potential best-in-class FGF21 treatment for MASH Efimosfermin clinical program to advance to Phase 3 pivotal study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback